- Home
- AG vs HCM Comparison
AG vs HCM Comparison
Compare AG & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AG
- HCM
- Stock Information
- Founded
- AG 1979
- HCM 2000
- Country
- AG Canada
- HCM Hong Kong
- Employees
- AG N/A
- HCM N/A
- Industry
- AG Precious Metals
- HCM Biotechnology: Pharmaceutical Preparations
- Sector
- AG Basic Materials
- HCM Health Care
- Exchange
- AG Nasdaq
- HCM Nasdaq
- Market Cap
- AG 3.2B
- HCM 2.6B
- IPO Year
- AG N/A
- HCM N/A
- Fundamental
- Price
- AG $6.79
- HCM $15.16
- Analyst Decision
- AG Buy
- HCM Hold
- Analyst Count
- AG 2
- HCM 1
- Target Price
- AG $8.50
- HCM $19.00
- AVG Volume (30 Days)
- AG 20.8M
- HCM 83.2K
- Earning Date
- AG 05-07-2025
- HCM 03-19-2025
- Dividend Yield
- AG 0.27%
- HCM N/A
- EPS Growth
- AG N/A
- HCM N/A
- EPS
- AG N/A
- HCM 0.04
- Revenue
- AG $560,604,000.00
- HCM $630,201,000.00
- Revenue This Year
- AG $62.81
- HCM $28.98
- Revenue Next Year
- AG $15.26
- HCM $20.41
- P/E Ratio
- AG N/A
- HCM $69.01
- Revenue Growth
- AG N/A
- HCM N/A
- 52 Week Low
- AG $4.43
- HCM $12.84
- 52 Week High
- AG $8.44
- HCM $21.92
- Technical
- Relative Strength Index (RSI)
- AG 62.89
- HCM 50.89
- Support Level
- AG $6.76
- HCM $14.00
- Resistance Level
- AG $7.10
- HCM $16.64
- Average True Range (ATR)
- AG 0.31
- HCM 0.45
- MACD
- AG 0.01
- HCM -0.12
- Stochastic Oscillator
- AG 70.77
- HCM 51.70
About AG First Majestic Silver Corp. (Canada)
First Majestic Silver Corp is engaged in the production, development, exploration, and acquisition of mineral properties with a focus on silver and gold production in North America. It owns three producing mines in Mexico consisting of the San Dimas Silver/Gold Mine, the Santa Elena Silver/Gold Mine, and the La Encantada Silver Mine.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.